MoFo News Item

MoFo Advises ARCH Venture Partners and GV on Their Investment in ROME Therapeutics

01 May 2020

Morrison & Foerster advised lead investors ARCH Venture Partners and GV in connection with a Series A financing round for $50 million in newly-launched Rome Therapeutics, a Cambridge, Mass.-based biotechnology startup leveraging repeatome for drug development.

ROME Therapeutics was founded to discover and develop novel therapies for cancer and autoimmune diseases by leveraging new insights from the vast uncharted territory of the repeatome. Its long-term goal is to find new drugs that drive cancer and autoimmune diseases into sustained remission.

The MoFo deal team was led by Boston-based corporate partner Ori Solomon, co-chair of the firm’s Emerging Companies + Venture Capital Group, and included ECVC of counsel Lee Shepard and associate Shiri Shenhav, and executive compensation partner Ron Aizen.

Read the press release.




Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.